^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) + Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-line anlotinib-based combination treatment for patients with advanced non-small cell lung cancer: A three arms, prospective study.
Published date:
05/19/2021
Excerpt:
...locally advanced or metastatic NSCLC patients with EGFR mutation (exon 19 deletion or L858R) (Cohort A) receive anlotinib (10 mg QD from day 1 to 14 of a 21-day cycle) and erlotinib...In Cohort A, 26 patients achieved confirmed PR, the ORR was 92.9%, and DCR was 96.4%. Median PFS was 20.53 months, and the 12-month PFS rate was 81.5%....For EGFR-mutated positive patients, anlotinib plus erlotinib shows good efficacy and well tolerability.
DOI:
10.1200/JCO.2021.39.15_suppl.e21073
Trial ID:
Source:
Title:
P76.10 - Erlotinib Plus Anlotinib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: An Open-Label, Phase 2 Study
Published date:
01/12/2021
Excerpt:
...NSCLC patients with previously untreated, EGFR mutation (exon 19 deletion or L858R) received anlotinib (10 mg QD from day 1 to 14 of a 21-day cycle) and erlotinib (at a dose of 150 mg once daily)...57 of the patients received at least once tumor assessment. 51 of them achieved partial response, 6 of them had stable disease and no patients had disease progression. The ORR was 89.5%, while the DCR was 100 %.
Trial ID:
